Investigational drug · Phase 2
SKB315
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Gastroesophageal Junction Adenocarcinoma.
Phase 2Last checked: Nov 19, 2026Latest source record: May 27, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "SKB315"
First trial start
2026
Jun 30, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "SKB315", any sponsor or status.
Conditions studied
As listed on its trial records.
- Gastroesophageal Junction Adenocarcinoma
Approved drugs for the same conditions: Stomach and esophageal cancer · Oncology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "SKB315" as an intervention, largest first.
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.Industry
NCT05367635 · 246 participants (planned) · Start Mar 16, 2022 · Primary completion Jun 30, 2026
Drug: SKB315 for injection; Drug: Tagitanlimab Drug: Capecitabine · For: Advanced Solid Tumors
Sites: Tianjin, China
- SKB315 in Combination Therapy in Patients With Advanced or Metastatic GC/ GEJ AdenocarcinomaNot yet recruiting
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.Industry
NCT07609667 · 80 participants (planned) · Start Jun 30, 2026 · Primary completion Jun 30, 2028
Drug: Tislelizumab; SKB315 for injection and 1 more · For: Gastroesophageal Junction Adenocarcinoma
Sites: Beijing, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Gastroesophageal Junction Adenocarcinoma
- CadonilimabAK104Phase 331 trials
Akeso · Hepatocellular Carcinoma, Gastric / Gastroesophageal Junction Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
- RilvegostomigAZD2936Phase 325 trials
AstraZeneca · Biliary Tract Cancer, Gastric Cancer, Non-small Cell Lung Cancer
- AZD0901Sonesitatug vedotin, CMG901Phase 36 trials
AstraZeneca · Gastric Cancer, Gastroesophageal Junction Cancer, Gastroesophageal Adenocarcinoma
- BudigalimabABBV-181Phase 36 trials
AbbVie · Hepatocellular Carcinoma, Non Small Cell Lung Carcinoma, c-MET
- QLS31905Phase 35 trials
Qilu Pharmaceutical Co., Ltd. · Advanced Solid Tumor, CLDN18.2-positive Advanced Biliary Tract Cancer, Gastric Adenocarcinoma
- SHR-A1904Phase 35 trials
Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Second-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma, Biliary Tract Cancer, Advanced Solid Tumors
- IBI343Arcotatug TavatecanPhase 34 trials
Innovent Biologics (Suzhou) Co. Ltd. · CLDN18.2 Positive, Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma, Primary Gastric Adenocarcinoma
- ASKB589Phase 33 trials
AskGene Pharma, Inc. · Gastric Cancer, Gastroesophageal Cancer (GC), Malignant Solid Tumor
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.